

Office of Regulatory Management  
Economic Review Form

<b>Agency name</b>	Department of Medical Assistance Services
<b>Virginia Administrative Code (VAC) Chapter citation(s)</b>	NA
<b>VAC Chapter title(s)</b>	NA
<b>Action title</b>	Virginia Medicaid Preferred Drug List / Common Core Formulary Changes, 90 Day Supply List Changes, FDA Approval of Over-the-Counter Naloxone, and Drug Utilization Review Board Approved Drug Service Authorizations
<b>Date this document prepared</b>	April 26, 2023
<b>Regulatory Stage (including Issuance of Guidance Documents)</b>	Issuance of Guidance Document

**Cost Benefit Analysis**

Complete Tables 1a and 1b for all regulatory actions. You do not need to complete Table 1c if the regulatory action is required by state statute or federal statute or regulation and leaves no discretion in its implementation.

Table 1a should provide analysis for the regulatory approach you are taking. Table 1b should provide analysis for the approach of leaving the current regulations intact (i.e., no further change is implemented). Table 1c should provide analysis for at least one alternative approach. You should not limit yourself to one alternative, however, and can add additional charts as needed.

Report both direct and indirect costs and benefits that can be monetized in Boxes 1 and 2. Report direct and indirect costs and benefits that cannot be monetized in Box 4. See the ORM Regulatory Economic Analysis Manual for additional guidance.

**Table 1a: Costs and Benefits of the Proposed Changes (Primary Option)**

(1) Direct & Indirect Costs & Benefits (Monetized)	This Medicaid Memo notifies providers about updates to the Virginia Medicaid’s fee-for-service Preferred Drug List (PDL) Program, 90-day supply list, naloxone FDA approval status, and drug service authorization requirements for drugs reviewed by the Department’s Pharmacy and Therapeutics Committee (P&T) and the Drug Utilization Review (DUR) Board. Although DMAS is not aware of any quantified benefits for the state, the benefit of this Memo is to provide updated information to the regulatory community. There are no costs associated with the Memo.	
(2) Present Monetized Values	Direct & Indirect Costs	Direct & Indirect Benefits
	(a)	(b)
(3) Net Monetized Benefit		
(4) Other Costs & Benefits (Non-Monetized)		
(5) Information Sources		

**Table 1b: Costs and Benefits under the Status Quo (No change to the regulation)**

(1) Direct & Indirect Costs & Benefits (Monetized)	The costs and/or benefits under the Status Quo will be included in the Economic Review Form that accompanies any regulatory action that may result from the guidance document.	
(2) Present Monetized Values	Direct & Indirect Costs	Direct & Indirect Benefits
	(a)	(b)
(3) Net Monetized Benefit		
(4) Other Costs & Benefits (Non-Monetized)		

(5) Information Sources	
-------------------------	--

**Table 1c: Costs and Benefits under Alternative Approach(es)**

(1) Direct & Indirect Costs & Benefits (Monetized)	The costs and/or benefits under an Alternative Approach(es) will be included in the Economic Review Form that accompanies any regulatory action that may result from the guidance document.	
(2) Present Monetized Values	Direct & Indirect Costs	Direct & Indirect Benefits
	(a)	(b)
(3) Net Monetized Benefit		
(4) Other Costs & Benefits (Non-Monetized)		
(5) Information Sources		

**Impact on Local Partners**

Use this chart to describe impacts on local partners. See Part 8 of the ORM Cost Impact Analysis Guidance for additional guidance.

**Table 2: Impact on Local Partners**

(1) Direct & Indirect Costs & Benefits (Monetized)	The costs and/or benefits on local partners will be included in the Economic Review Form that accompanies any regulatory action that may result from the guidance document.	
(2) Present Monetized Values	Direct & Indirect Costs	Direct & Indirect Benefits
	(a)	(b)
(3) Other Costs & Benefits (Non-Monetized)		

(4) Assistance	
(5) Information Sources	

**Impacts on Families**

Use this chart to describe impacts on families. See Part 8 of the ORM Cost Impact Analysis Guidance for additional guidance.

**Table 3: Impact on Families**

(1) Direct & Indirect Costs & Benefits (Monetized)	The costs and/or benefits on families will be included in the Economic Review Form that accompanies any regulatory action that may result from the guidance document.	
(2) Present Monetized Values	Direct & Indirect Costs	Direct & Indirect Benefits
	(a)	(b)
(3) Other Costs & Benefits (Non-Monetized)		
(4) Information Sources		

**Impacts on Small Businesses**

Use this chart to describe impacts on small businesses. See Part 8 of the ORM Cost Impact Analysis Guidance for additional guidance.

**Table 4: Impact on Small Businesses**

(1) Direct & Indirect Costs & Benefits (Monetized)	The costs and/or benefits on small businesses will be included in the Economic Review Form that accompanies any regulatory action that may result from the guidance document.	
(2) Present Monetized Values	Direct & Indirect Costs	Direct & Indirect Benefits
	(a)	(b)

(3) Other Costs & Benefits (Non-Monetized)	
(4) Alternatives	
(5) Information Sources	

**Changes to Number of Regulatory Requirements**

**Table 5: Regulatory Reduction**

For each individual action, please fill out the appropriate chart to reflect any change in regulatory requirements, costs, regulatory stringency, or the overall length of any guidance documents.

*Length of Guidance Documents (only applicable if guidance document is being revised)*

<b>Title of Guidance Document</b>	<b>Original Length</b>	<b>New Length</b>	<b>Net Change in Length</b>
Virginia Medicaid Preferred Drug List / Common Core Formulary Changes, 90 Day Supply List Changes, FDA Approval of Over-the-Counter Naloxone, and Drug Utilization Review Board Approved Drug Service Authorizations	0	824 words	824 words